On November 16, 2026, Vanda Pharmaceuticals Inc. entered into a Confidential Settlement and License Agreement with MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited. This settlement resolves Vanda's patent infringement litigation against MSN regarding its sleep aid medication, HETLIOZ LQ (tasimelteon suspension, 4 mg/ml), which MSN sought to market as a generic.
The agreement allows MSN to manufacture, import, and market its generic version of HETLIOZ LQ in the U.S. starting from the License Effective Date, set for the first quarter of 2040. However, MSN may enter the market earlier under certain conditions, such as patent expiration or a court ruling that invalidates the patents.
Vanda Pharmaceuticals, incorporated in Delaware, operates within the pharmaceutical preparations sector, specifically focusing on developing and commercializing innovative medicines. The company trades under the ticker VNDA on the Nasdaq exchange. This recent settlement is a significant step in Vanda's strategy to manage its intellectual property and market presence against generic competition.
The settlement also includes provisions for MSN to engage in pre-launch activities, such as customer discussions and pricing negotiations, ahead of the official launch. Additionally, if Vanda grants any other party more favorable terms regarding market entry or pre-launch rights, MSN will benefit from those terms as well.
The agreement requires Vanda and MSN to submit the settlement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. This settlement provides a full resolution to the claims asserted in the litigation, which Vanda initiated to protect its patents on HETLIOZ LQ.
As part of the agreement, MSN acknowledges the validity and enforceability of the patents asserted in the litigation and agrees not to challenge them, barring certain exceptions. The parties will file a stipulated order with the Court to dismiss all claims in the litigation and seek approval for a consent judgment and permanent injunction, which would restrict MSN from producing the generic without a license from Vanda.
Details about the Settlement Agreement will be included in Vanda's forthcoming Annual Report on Form 10-K for the fiscal year ending December 31, 2026. The outcome of this settlement may influence other companies in the pharmaceutical preparations industry, particularly those involved in developing generic drugs.
In summary, Vanda's settlement with MSN Pharmaceuticals marks a crucial development in the management of its patent portfolio and sets the stage for future market dynamics in the pharmaceutical sector.
Read Next
AB Private Lending Fund Reports Unregistered Share Sale and Distributions
Blackstone Private Credit Fund Announces Share Sale, Distributions
Vista Energy repurchases 30,000 Series A shares
HSBC announces results of $1.5 billion tender offer
Westlake Corp settles PVC antitrust lawsuits for $199 million
SELLAS Life Sciences announces $161.8 million public offering








